167 related articles for article (PubMed ID: 27290668)
1. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
[TBL] [Abstract][Full Text] [Related]
3. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
7. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir.
Jain P; Thota A; Saini PK; Raghuvanshi RS
Crit Rev Anal Chem; 2024; 54(2):401-415. PubMed ID: 35617468
[TBL] [Abstract][Full Text] [Related]
13. A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
Grégoire M; Deslandes G; Renaud C; Bouquié R; Allavena C; Raffi F; Jolliet P; Dailly E
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():1-9. PubMed ID: 25261833
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Prathipati PK; Mandal S; Destache CJ
J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
Elliot E; Amara A; Jackson A; Moyle G; Else L; Khoo S; Back D; Owen A; Boffito M
J Antimicrob Chemother; 2016 Apr; 71(4):1031-6. PubMed ID: 26679246
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of HIV integrase inhibitors.
Adams JL; Greener BN; Kashuba AD
Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
19. Update on raltegravir and the development of new integrase strand transfer inhibitors.
Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
[TBL] [Abstract][Full Text] [Related]
20. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Yamada E; Takagi R; Moro H; Sudo K; Kato S
PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
